Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27791784 | 0.82 | KMT2A (0.50) | KMT2AMEN1APEX1ALDH1A1HPGD | |
| SCHEMBL17582651 | 0.78 | LDHA (0.42) | KMT2AMEN1APEX1POLBALDH1A1 | |
| SCHEMBL27623807 | 0.76 | GAA (0.39) | KMT2AMEN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL7376159 | 0.74 | KMT2A (0.59) | KMT2AMEN1APEX1ALDH1A1MCL1 | |
| SCHEMBL6942194 | 0.74 | KMT2A (0.59) | KMT2AMEN1APEX1ALDH1A1HPGD | |
| SCHEMBL12499910 | 0.72 | — | — | |
| SCHEMBL28443819 | 0.72 | KMT2A (0.57) | KMT2AMEN1APEX1POLBALDH1A1 | |
| SCHEMBL15349677 | 0.72 | KMT2A (0.57) | KMT2AMEN1APEX1ALDH1A1MCL1 | |
| SCHEMBL3907975 | 0.72 | TTR (0.58) | KMT2AMEN1APEX1POLBALDH1A1 | |
| SCHEMBL752776 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603360-B2 | Method for producing purified dialkyl-furan-2,5-dicarboxylate | EASTMAN CHEMICAL COMPANY (US) | 2023-03-14 | — | — | US | claimed |
| US-20200331879-A1 | METHOD FOR PRODUCING PURIFIED DIALKYL-FURAN-2,5-DICARBOXYLATE | EASTMAN CHEMICAL COMPANY (US) | 2020-10-22 | — | — | US | claimed |
| US-10696645-B2 | Method for producing purified dialkyl-furan-2,5-dicarboxylate | EASTMAN CHEMICAL COMPANY (US) | 2020-06-30 | — | — | US | claimed |
| US-20190023676-A1 | METHOD FOR PRODUCING PURIFIED DIALKYL-FURAN-2,5-DICARBOXYLATE | EASTMAN CHEMICAL COMPANY (US) | 2019-01-24 | — | — | US | claimed |
| CN-110172049-B | Method for preparing furan-2, 5-dimethyl diformate by oxidizing and esterifying 5-hydroxymethylfurfural | 中国科学院大连化学物理研究所 | 2021-01-05 | — | — | CN | disclosed |
| EP-2994459-B1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FURAN-2,5-DICARBOXYLIC ACID OR DERIVATIVES THEREOF | STICHTING WAGENINGEN RES (NL) | 2017-10-04 | — | — | EP | disclosed |
| US-9376414-B2 | Process and intermediates for the production of furan-2,5-dicarboxylic acid or derivatives thereof | STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL) | 2016-06-28 | — | — | US | disclosed |
| US-20160075672-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FURAN-2,5-DICARBOXYLIC ACID OR DERIVATIVES THEREOF | STICHTING WAGENINGEN RESEARCH (NL) | 2016-03-17 | — | — | US | disclosed |
| EP-2994459-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FURAN-2,5-DICARBOXYLIC ACID OR DERIVATIVES THEREOF | Stichting Dienst Landbouwkundig Onderzoek (NL) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014078197-A1 | 2-THIO-1,3,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-8729110-B1 | 2-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729110-B1 | 2-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066115-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RARϜ RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6730675-B2 | SUCH AS 7-CHLORO-4-HYDROXY-2-(2,5-DIMETHYL(3-FURANYL)) METHYL-1,2,5,10-TETRAHYDROPYRIDAZINO(4,5-B)QUINOLINE-1,10-DIONE WHICH BINDS NMDA RECEPTORS (N-METHYL-ASPARTIC ACID RECEPTORS); NEUROPATHY | ASTRAZENECA AB (SE) | 2004-05-04 | — | — | US | disclosed |
| US-20030153572-A1 | Compounds and methods for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | disclosed |
| EP-1244664-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047925-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331879-A1 | METHOD FOR PRODUCING PURIFIED DIALKYL-FURAN-2,5-DICARBOXYLATE | DDC, ACACA, ACACB | KMT2A 2257/4885MEN1 3993/4885APEX1 3587/4885 |
| US-10696645-B2 | Method for producing purified dialkyl-furan-2,5-dicarboxylate | DDC, ACACA, ACACB | KMT2A 2257/4885MEN1 3993/4885APEX1 3587/4885 |
| US-20160075672-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FURAN-2,5-DICARBOXYLIC ACID OR DERIVATIVES THEREOF | PGD, UROD, PCK1 | KMT2A 2987/4885MEN1 4559/4885APEX1 2220/4885 |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | RARB, RARG, RARA | KMT2A 3182/4885MEN1 4853/4885APEX1 4482/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | KMT2A 4366/4885MEN1 4879/4885APEX1 3176/4885 |
| US-20030153572-A1 | Compounds and methods for the treatment of pain | OPRK1, ACHE, OPRD1 | KMT2A 4195/4885MEN1 4269/4885APEX1 3888/4885 |
| US-20190023676-A1 | METHOD FOR PRODUCING PURIFIED DIALKYL-FURAN-2,5-DICARBOXYLATE | DDC, ACACA, ACACB | KMT2A 2257/4885MEN1 3993/4885APEX1 3587/4885 |
| US-11603360-B2 | Method for producing purified dialkyl-furan-2,5-dicarboxylate | DDC, ACACA, ACACB | KMT2A 2257/4885MEN1 3993/4885APEX1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.